Grauslund J, Taha AA, Molander LD, Kawasaki R, Mller S, Hjlund K, Stokholm L (2024) Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes
Sulfonylureas (glipizide, glyburide, glimepiride) cause non-glucose-dependent insulin release, meaning they push insulin out regardless of blood sugar level
Other side effects Additional reported side effects include: Joint pain and water retention Muscle and joint aches Headaches and nausea Receptor desensitization with prolonged use Potential suppression of natural GH and IGF-1 production Who should avoid IGF-1 LR3 Certain groups should not use IGF-1 LR3: Anyone with active cancer or tumor history Those with severe insulin resistance or diabetes Pregnant or nursing women Anyone under 25 whose growth plates haven't closed Those with existing hormonal imbalances IGF-1 LR3 is not FDA-approved for general medical use and remains primarily a research compound
The committee makes recommendations to the FDA, which holds final authority
